Trial Profile

A Clinical Collaboration Trial with Targovax TG Mutant RAS Vaccine in Combination with Other Treatments in Late Stage Pancreatic Cancer

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 25 Mar 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Mar 2019 New trial record
15 Mar 2019 According to a Targovax media release, PICI will be the sponsor and responsible for running this clinical trial and scientific analyses, CRI and PICI co-organize the immunotherapy experts, and Targovax will be responsible for TG supply. Targovax may also contribute by partial cost sharing of the trial. The design of this first clinical trial is currently under discussion.
15 Mar 2019 According to a Targovax media release, the company has entered into an agreement with The Parker Institute for Cancer Immunotherapy (PICI) and the Cancer Research Institute (CRI) for a clinical collaboration with Targovax TG mutant RAS vaccine (TG) and plan to conduct this clinical collaboration trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com